**Amendments to the Claims**:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one, wherein it contains, as an active ingredient, 0.1 to 30 percent by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:




or a medically acceptable salt thereof in an aqueous base

wherein the aqueous base comprises: a water-soluble polymer selected from the group consisting of ~~polyacrylamide, polyethylene imine, carboxy vinyl polymer, starch acrylate, ethyl vinyl acetate, starch, and Eudragid~~sodium polyacrylate, starch acrylate and methyl acrylate/acrylic acid 2-ethylhexyl copolymer resin emulsion; a cross-linking agent; and a polyhydric alcohol and water.

2. (Canceled)

3. (Currently Amended) The percutaneous absorption preparation according to claim 1, wherein the aqueous base contains, based on a total amount of the aqueous base, 1 to 20 percent by mass of a water-soluble polymer, 0.01 to 20 percent by mass of a cross-linking agent, 10 to 80 percent by mass of polyhydric alcohol, and 1 to 80 percent by mass of water.

4-5. (Canceled)

6. (Currently Amended) A percutaneous absorption adhesive preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one, wherein a support medium, a base layer




formed of an aqueous base containing, as an active ingredient, 0.1 to 30 percent by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:
or a medically acceptable salt thereof, and a liner are sequentially laminated and formed,

wherein the aqueous base comprises: a water-soluble polymer selected from the group consisting of polyacrylamide, polyethylene imine, carboxy vinyl polymer, starch acrylate, ethyl vinyl acetate, ~~starch, and Eudragid~~and starch; a cross-linking agent; a polyhydric alcohol and water.

7. (Canceled)

8. (Previously Presented) The percutaneous absorption adhesive preparation according to claim 6, wherein the aqueous base contains, based on a total amount of the aqueous base, 1 to 20 percent by mass of a water-soluble polymer, 0.01 to 20 percent by mass of a cross-linking agent, 10 to 80 percent by mass of polyhydric alcohol, and 1 to 80 percent by mass of water.

9-10. (Canceled)

11. (Currently Amended) The percutaneous absorption adhesive preparation according to claim 1, wherein the preparation is used for treating arteriosclerosis, hepatic damage, ~~rental~~ retinal damage, diabetes or gastrointestinal mucous membrane damage.

12. (Canceled)

13. (New) The percutaneous absorption preparation according to claim 1, wherein the cross-linking agent is aluminum hydroxide.

14. (New) The percutaneous absorption preparation according to claim 1, wherein the polyhydric alcohol is glycerin.

15. (New) The percutaneous absorption preparation according to claim 1, further comprising N-methyl-2-pyrrolidone as a dissolving agent.

16. (New) The percutaneous absorption preparation according to claim 1, further comprising crotamiton as a percutaneous absorption accelerator.

17. (New) The percutaneous absorption preparation according to claim 1, further comprising tartatic acid as a speed adjuster.